HLS Therapeutics
Market Cap
CA$450.7m
Last Updated
2019/10/18 00:51 UTC
Data Sources
Company Financials +
Executive Summary
HLS Therapeutics Inc., a specialty pharmaceutical company, focuses on acquiring and commercializing pharmaceutical products in the specialty central nervous system and cardiovascular markets.
Snowflake
Fundamentals
Mediocre balance sheet and overvalued.
Similar Companies
Share Price & News
How has HLS Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
1.1%
HLS
1.9%
CA Healthcare
0.1%
CA Market
1 Year Return
-4.5%
HLS
-10.3%
CA Healthcare
1.6%
CA Market
Return vs Industry: HLS exceeded the Canadian Healthcare industry which returned -10.3% over the past year.
Return vs Market: HLS underperformed the Canadian Market which returned 1.6% over the past year.
Shareholder returns
| HLS | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.1% | 1.9% | 0.1% |
| 30 Day | 3.5% | 1.7% | -2.9% |
| 90 Day | -19.7% | -7.7% | -1.4% |
| 1 Year | -3.3%-4.5% | -7.9%-10.3% | 5.2%1.6% |
| 3 Year | n/a | -0.5%-14.4% | 13.8%3.7% |
| 5 Year | n/a | 58.9%19.0% | 25.3%7.2% |
Price Volatility Vs. Market
How volatile is HLS Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
A Look At The Fair Value Of HLS Therapeutics Inc. (TSE:HLS)1 month ago | Simply Wall St
Should HLS Therapeutics Inc. (TSE:HLS) Be Part Of Your Income Portfolio?Valuation
Is HLS Therapeutics undervalued compared to its fair value and its price relative to the market?
1.78x
Price to Book (PB) ratio
Share Price vs. Fair Value
Undervalued: HLS (CA$14.66) is trading above our estimate of fair value (CA$13.73)
Significantly Undervalued: HLS is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: HLS is unprofitable, so we can't compare its PE Ratio to the Healthcare industry average.
PE vs Market: HLS is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate HLS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HLS is good value based on its PB Ratio (1.8x) compared to the CA Healthcare industry average (2.5x).
Next Steps
Future Growth
How is HLS Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
27.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HLS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HLS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HLS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HLS's revenue (17.5% per year) is forecast to grow faster than the Canadian market (5.8% per year).
High Growth Revenue: HLS's revenue (17.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: Insufficient data to determine if HLS's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has HLS Therapeutics performed over the past 5 years?
-30.1%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: HLS is unprofitable, and losses have increased over the past 5 years at a rate of -30.1% per year.
Accelerating Growth: Unable to compare HLS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HLS is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-46%).
Return on Equity
High ROE: HLS has a negative Return on Equity (-12.79%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: HLS is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: HLS is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is HLS Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: HLS's short term assets ($66.9M) exceeds its short term liabilities ($39.3M)
Long Term Liabilities: HLS's short term assets (66.9M) do not cover its long term liabilities (102.4M)
Debt to Equity History and Analysis
Debt Level: HLS's debt to equity ratio (50.1%) is considered high
Reducing Debt: Insufficient data to determine if HLS's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Inventory Level: HLS has a low level of unsold assets or inventory.
Debt Coverage by Assets: HLS's debt is not covered by short term assets (assets are 0.7x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable HLS has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: HLS is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 31.3% per year.
Next Steps
Dividend
What is HLS Therapeutics's current dividend yield, its reliability and sustainability?
1.34%
Current Dividend Yield
Upcoming Dividend Payment
Purchase HLS Therapeutics before the 'Buy Limit' to receive their next dividend payment.
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: HLS's dividend (1.34%) isn’t notable compared to the bottom 25% of dividend payers in the Canadian market (2.01%).
High Dividend: HLS's dividend (1.34%) is low compared to the top 25% of dividend payers in the Canadian market (6.01%).
Stable Dividend: Too early to tell whether HLS's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if HLS's dividend payments are increasing as they only just started paying a dividend.
Current Payout to Shareholders
Dividend Coverage: HLS is paying a dividend but the company is unprofitable.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
What is the CEO of HLS Therapeutics's salary, the management and board of directors tenure and is there insider trading?
1.8yrs
Average management tenure
CEO
Greg Gubitz (62yo)
5.3yrs
Tenure
US$1,222,437
Compensation
Mr. Gregory David Gubitz, also known as Greg, B.A., LL.B, is Co-Founder of HLS Therapeutics Inc. and serves as its Chief Executive Officer and Director. Mr. Gubitz serves as an Executive Officer for MDS, IÂ ...
CEO Compensation Analysis
Compensation vs. Market: Insufficient data to establish whether Greg's total compensation is reasonable compared to companies of similar size in the Canadian market.
Compensation vs Earnings: Greg's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
1.8yrs
Average Tenure
58yo
Average Age
Experienced Management: HLS's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Age and Tenure
4.2yrs
Average Tenure
61yo
Average Age
Experienced Board: HLS's board of directors are considered experienced (4.2 years average tenure).
Insider Trading
Insider Buying: HLS insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Company |
| Shares | 673,145 |
| Max Price | US$13.50 |
| Entity | Individual |
| Role | Chief Legal Officer General Counsel & Corporate Secretary |
| Shares | 500 |
| Max Price | US$13.50 |
| Entity | Individual |
| Role | Chief Executive Officer Co-Founder |
| Shares | 3,000 |
| Max Price | US$14.54 |
| Entity | Individual |
| Role | President President & COO |
| Shares | 5,000 |
| Max Price | US$14.30 |
| Entity | Individual |
| Role | Chairman of the Board Co-Founder & Executive Chairman |
| Shares | 20,000 |
| Max Price | US$14.00 |
| Entity | Individual |
| Role | Chairman of the Board Co-Founder & Executive Chairman |
| Shares | 10,000 |
| Max Price | US$15.50 |
| Entity | Individual |
| Role | Chairman of the Board Co-Founder & Executive Chairman |
| Shares | 200,000 |
| Max Price | US$15.50 |
Ownership Breakdown
Management Team
Greg Gubitz (62yo)
Co-Founder
- Tenure: 5.3yrs
- Compensation: US$1.22m
Bill Wells (58yo)
Co-Founder & Executive Chairman
- Tenure: 5.3yrs
- Compensation: US$907.12k
Gilbert Godin (60yo)
President & COO
- Tenure: 5.5yrs
- Compensation: US$1.20m
Sanjiv Sharma (63yo)
Chief Commercial Officer
- Tenure: 1.1yrs
- Compensation: US$658.52k
Hemanth Varghese (43yo)
Head of Corporate Strategy & Business Development
- Tenure: 2.1yrs
Tim Hendrickson (47yo)
Chief Financial Officer
- Tenure: 1.1yrs
- Compensation: US$481.59k
Ryan Lennox (38yo)
General Counsel & Corporate Secretary
- Tenure: 1.4yrs
Board Members
Greg Gubitz (62yo)
Co-Founder
- Tenure: 5.3yrs
- Compensation: US$1.22m
Laura Brege (61yo)
Independent Director
- Tenure: 0.8yrs
J. Lanthier (78yo)
Independent Director
- Tenure: 4.2yrs
- Compensation: US$194.95k
Bill Wells (58yo)
Co-Founder & Executive Chairman
- Tenure: 5.3yrs
- Compensation: US$907.12k
Don DeGolyer (57yo)
Independent Director
- Tenure: 1.6yrs
- Compensation: US$54.15k
Yvon Bastien (72yo)
Independent Director
- Tenure: 4.2yrs
- Compensation: US$178.92k
Rodney Hill (51yo)
Independent Director
- Tenure: 4.6yrs
- Compensation: US$54.82k
Company Information
HLS Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: HLS Therapeutics Inc.
- Ticker: HLS
- Exchange: TSX
- Founded:
- Industry: Health Care Distributors
- Sector: Healthcare
- Market Cap: CA$450.664m
- Shares outstanding: 30.74m
- Website: https://www.hlstherapeutics.com
Number of Employees
Location
- HLS Therapeutics Inc.
- 10 Carlson Court
- Suite 701
- Toronto
- Ontario
- M9W 6L2
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| HLS | TSX (The Toronto Stock Exchange) | Yes | Common Shares | CA | CAD | Mar 2018 |
| HLTR.F | OTCPK (Pink Sheets LLC) | Yes | Common Shares | US | USD | Mar 2018 |
Biography
HLS Therapeutics Inc., a specialty pharmaceutical company, focuses on acquiring and commercializing pharmaceutical products in the specialty central nervous system and cardiovascular markets. It markets Cl ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/18 00:51 |
| End of Day Share Price | 2019/10/17 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.